Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.50 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 5/20 | 0.38 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.38 |
| ▸ | ERBB3 | P21860 | 5/20 | 0.38 |
| ▸ | ERBB4 | Q15303 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13768011 | 0.78 | KDM4E (0.49) | DYRK1APDPK1IRAK4EGFRERBB2 | |
| SCHEMBL13186164 | 0.74 | DYRK1A (0.59) | DYRK1AIRAK4EGFRERBB2ERBB3 | |
| SCHEMBL16432196 | 0.73 | TRPA1 (0.55) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL4001800 | 0.73 | CDC7 (0.60) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL4062331 | 0.72 | KDR (0.39) | DYRK1APDPK1MEN1KMT2AMAPK1 | |
| SCHEMBL10164779 | 0.70 | DYRK1A (0.46) | DYRK1AIRAK4EGFRERBB2ERBB3 | |
| SCHEMBL3575456 | 0.70 | TRPA1 (0.51) | DYRK1AEGFRERBB2ERBB3ERBB4 | |
| SCHEMBL4544688 | 0.70 | TTBK1 (0.64) | PDPK1EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL23035074 | 0.70 | HSD17B10 (0.46) | EGFRERBB2ERBB3ERBB4KMT2A | |
| SCHEMBL397656 | 0.69 | DYRK1A (0.59) | DYRK1AIRAK4EGFRMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115298180-B | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 日本理化学研究所 | 2025-06-10 | — | — | CN | disclosed |
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | FLASH THERAPEUTICS, LLC (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| CN-115707705-A | Aromatic heterocyclic compound, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-4121430-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | Flash Therapeuttics, LLC (US) | 2023-01-25 | — | — | EP | disclosed |
| CN-115298180-A | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | 富雷旭医疗有限责任公司 | 2022-11-04 | — | — | CN | disclosed |
| EP-3450436-B1 | CONDENSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-07-27 | — | — | EP | disclosed |
| US-11390634-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-07-19 | — | — | US | disclosed |
| CN-109415384-B | Fused heterocyclic compound | 武田药品工业株式会社 | 2022-01-11 | — | — | CN | disclosed |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2021-09-30 | — | — | US | disclosed |
| WO-2021188417-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | FLASH THERAPEUTICS, LLC (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20210115067-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-22 | — | — | US | disclosed |
| US-10981934-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-20 | — | — | US | disclosed |
| US-20200140462-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-05-07 | — | — | US | disclosed |
| US-10577382-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-03-03 | — | — | US | disclosed |
| US-20190106437-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-04-11 | — | — | US | disclosed |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2017-05-11 | — | — | US | disclosed |
| US-9580428-B2 | Compositions and methods for inhibiting viral polymerase | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. | 2015-07-09 | — | — | US | disclosed |
| WO-2013158746-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11963960-B2 | Compounds for treating or inhibiting recurrence of acute myeloid leukemia | MCL1, FLT3, ABL1 | DYRK1A 1919/4885PDPK1 1734/4885IRAK4 1217/4885 |
| US-20200140462-A1 | FUSED HETEROCYCLIC COMPOUND | REN, BRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DYRK1A 4850/4885PDPK1 3787/4885IRAK4 4189/4885 |
| US-20170128454-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | DYRK1A 4874/4885PDPK1 2363/4885IRAK4 3710/4885 |
| US-20150191472-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL POLYMERASE | POLRMT, POLR1E, POLR1A | DYRK1A 4874/4885PDPK1 2363/4885IRAK4 3710/4885 |
| US-10577382-B2 | Fused heterocyclic compound | REN, BRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DYRK1A 4858/4885PDPK1 3778/4885IRAK4 4107/4885 |
| US-20210299128-A1 | COMPOUNDS FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA | MCL1, FLT3, ABL1 | DYRK1A 1919/4885PDPK1 1734/4885IRAK4 1217/4885 |
| US-10981934-B2 | Fused heterocyclic compound | REN, BRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DYRK1A 4850/4885PDPK1 3787/4885IRAK4 4189/4885 |
| US-11390634-B2 | Fused heterocyclic compound | REN, BRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DYRK1A 4850/4885PDPK1 3787/4885IRAK4 4189/4885 |
| US-20210115067-A1 | FUSED HETEROCYCLIC COMPOUND | REN, BRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DYRK1A 4850/4885PDPK1 3787/4885IRAK4 4189/4885 |
| US-20190106437-A1 | FUSED HETEROCYCLIC COMPOUND | REN, BRD4, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | DYRK1A 4850/4885PDPK1 3787/4885IRAK4 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.